2018 – 今，副研究员，中国医学科学院&北京协和医学院，药物研究所；
2016 – 2018，助理研究员，中国医学科学院&北京协和医学院，药物研究所；
2015 – 2016，Staff Scientist，美国University of Tennessee Health Science Center, College of Medicine, Department of Pediatrics, Pulmonary Division；
2014 – 2015，Postdoctoral Fellow，美国University of Tennessee Health Science Center, College of Medicine, Department of Pediatrics, Pulmonary Division；
2009 – 2014，Postdoctoral Fellow，美国City of Hope National Medical Center and Beckman Research Institute, Department of Biology；
2004 – 2009，博士，首都师范大学，生命科学学院。
张晓颖副研究员的研究方向为肿瘤分子生物学。在美国的两任博士后研究，以及随后的Staff Scientist工作期间，承担的课题方向有：肝癌发生分子机制，衰老机制相关研究，肺部囊性纤维化的致病机理及临床病例个性化治疗方案的拟定。回国后，在中国医学科学院药物研究所工作，主要致力于肿瘤发生分子机制及相关药理研究。
1. F1099L-CFTR has impaired channel function and associates with mild disease phenotypes in two pediatric patients, Xiaoying Zhang, Jaspal S. Hothi, Yanhui Zhang, Aixia Ren, Michael J. Rock, Saumini Srinivasen, Dennis C. Stokes, Anjaparavanda P. Naren, and Weiqiang Zhang, Life (Basel), 2021 Feb 8; 11(2):131.
2. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models, Jing Jin, Nina Xue, Yuan Liu, Rong Fu, Mingjin Wang, Ming Ji, Fangfang Lai, Jinping Hu, Xiaojian Wang, Qiong Xiao, Xiaoying Zhang, Dali Yin, Liping Bai, Xiaoguang Chen, Shuan Rao, Acta Pharm Sin B, 2020 Feb; 10(2): 276-288.
3. Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment, Ming Ji, Nina Xue, Fangfang Lai, Xiaoying Zhang, Sen Zhang, Yuchen Wang, Jing Jin, and Xiaoguang Chen, Biol Pharm Bull, 2018 Apr 1; 41(4): 592-596.
4. A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility, Yun-Tao Ma, Yanting Yang, Pei Cai, De-Yang Sun, Pedro A. Sanchez-Murcia, Xiaoying Zhang, Wen-Qiang Jia, Lei Lei, Mengqi Guo, Federico Gago, Hongbo Wang, and Wei-Shuo Fang, J Nat Prod, 2018 Mar 23; 81(3): 524-533.
5. Analysis of liver tumor-prone mouse models of the Hippo kinase scaffold proteins Rassf1a and Sav1, Xiaoying Zhang, Cai Guo, Xiwei Wu, Arthur X. Li, Limin Liu, Walter Tsark, Reinhard Dammann, Hui Shen, Steven Vonderfecht, and Gerd P. Pfeifer, Cancer Res, 2016 May 1; 76(9):2824-35.
6. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR, Weiqiang Zhang, Xiaoying Zhang, Yanhui Zhang, Dennis C. Stokes, Anjaparavanda Naren, Drugs Today (Barc), 2016 Apr; 52(4):229-237.
7. C. 3623 G>A mutation encodes a CFTR protein with impaired channel function, Xiaoying Zhang, Jaspal S. Hothi, Yanhui Zhang, Saumini Srinivasan, Dennis C. Stokes, Weiqiang Zhang, Respir Res, 2016 Jan 22; 17(1):8.
8. Longitudinal epigenetic and gene expression profiles analyzed by three –component analysis reveal down-regulation of genes involved in protein translation in human aging, Marc Jung*, Seung-Gi Jin*, Xiaoying Zhang*, Wenying Xiong, Grigoriy Gogoshin, Andrei S. Rodin, Gerd P. Pfeifer, * Equal Contributing Authors, Nucleic Acids Res, 2015 Sep 3;43(15):e100.
9. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinase MST1 and MST2, Cai Guo, Xiaoying Zhang, Gerd P. Pfeifer, J BiolChem, 2011 Feb 25;286(8): 6253-61.
10. CDK5RAP2 is required for spindle checkpoint function, Xiaoying Zhang, Dongyun Liu, Shuang Lv, Haibo Wang, Xueyan Zhong, Bo Liu, Bo Wang, Ji Liao, Jing Li, Gerd P. Pfeifer, Xingzhi Xu, Cell Cycle, 2009 Apr 15;8(8): 1206-16.
会议文章:
1. C. 2768 C>A CFTR is a disease-causing mutation, Xiaoying Zhang, Jaspal S. Hothi, Courtney Gushue, Saumini Srinivasan, Dennis C. Stokes, Weiqiang Zhang, Am. J. Respir. Crit. Care Med., 2016, 193:A5561.
2. C. 3623 G>A mutation encodes a CFTR protein with impaired channel function, Xiaoying Zhang, Jaspal S. Hothi, Xinglin Tan, Dennis C. Stokes, Weiqiang Zhang, Pediatr Pulmonol, 2015, 50(S41):203.
3. The rescued F508del-CFTR forms an inhibitory complex with NHERF2 and LPA2 at the cell surface, Xinglin Tan, Changsuk Moon, Xiaoying Zhang, Anjaparavanda P. Naren, Weiqiang Zhang, Pediatr Pulmonol, 2015, 50(S41):200.
